New pharmacologic findings for the treatment of PONV and PDNV

American Journal of Health-System Pharmacy

Volumn 66, Issue 1 SUPPL. 1, 2009, Pages

  Kloth, Dwight D ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Antiemetics; Mechanism of action; Palonosetron; Pharmacokinetics; Postoperative nausea and vomiting; Protocols

Indexed keywords

ANTIEMETIC AGENT; BUTYROPHENONE; CANNABINOID; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DROPERIDOL; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE; PROMETHAZINE; SCOPOLAMINE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON; CORTICOSTEROID; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; NEUROKININ 1 RECEPTOR; SEROTONIN ANTAGONIST;

ACUPRESSURE; ALLOSTERISM; BINDING AFFINITY; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; FINANCE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; OUTCOME ASSESSMENT; POSTOPERATIVE NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QT PROLONGATION; RECEPTOR BINDING; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; XEROSTOMIA; ARTICLE; DRUG ANTAGONISM; DRUG COMBINATION; HOSPITAL DISCHARGE;

ADRENAL CORTEX HORMONES; ANTIEMETICS; CHOLINERGIC ANTAGONISTS; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; HISTAMINE H1 ANTAGONISTS; HUMANS; PATIENT DISCHARGE; POSTOPERATIVE NAUSEA AND VOMITING; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS;

EID: 61549100574     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ashp080462     Document Type: Conference Paper

References (36)

1. Carroll NV, Miederhoff PA, Cox FM et al. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J Clin Anesth. 1994; 6:364-369
2. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992; 77:162-184
3. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983; 25 Suppl 1:1-7.
4. Gold BS, Kitz DS, Lecky JH et al. Unanticipated admission to the hospital following ambulatory surgery. JAMA. 1989; 262:3008-3010
5. Moertel CG, Reitemeier RJ, Gage RP. A Controlled Clinical Evaluation of Antiemetic Drugs. JAMA. 1963; 186:116-118
6. Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981; 305:905-909
7. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993; 329:1790-1796
8. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989; 7:108-114
9. Golembiewski J, Tokumaru S. Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting. J Perianesth Nurs. 2006; 21:385-397 (Pubitemid 44880820)
10. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs. 2007; 21:813-833
11. Chan MT, Choi KC, Gin T et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg. 2006; 103:1155-1162 (Pubitemid 44627339)
12. Wallenborn J, Gelbrich G, Bulst D et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. Br Med J. 2006; 333:324. (Pubitemid 44350395)
13. Gan TJ, Meyer TA, Apfel CC et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007; 105:1615-1628 (Pubitemid 350190555)
14. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000; 59:213-243 (Pubitemid 30168508)
15. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 2000; 23:215-228 (Pubitemid 30703298)
16. Silvestre JS, Prous JR. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find Exp Clin Pharmacol. 2007; 29:457-465
17. Gan TJ, White PF, Scuderi PE et al. FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified? Anesthesiology. 2002; 97:287.
18. Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health-Syst Pharm. 2007; 64:1174-1186
19. Rappaport BA. FDA response to droperidol black box warning editorials. Anesth Analg. 2008; 106:1585.
20. Fortney JT, Gan TJ, Graczyk S et al. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg. 1998; 86:731-738
21. Chia YY, Lo Y, Liu K et al. The effect of promethazine on postoperative pain: a comparison of preoperative, postoperative, and placebo administration in patients following total abdominal hysterectomy. Acta Anaesthesiol Scand. 2004; 48:625-630 (Pubitemid 38649595)
22. Keene JR, Buckley KM, Small S et al. Accidental intra-arterial injection: a case report, new treatment modalities, and a review of the literature. J Oral Maxillofac Surg. 2006; 64:965-968 (Pubitemid 43728132)
23. Einarsson JI, Audbergsson BO, Thorsteinsson A. Scopolamine for prevention of postoperative nausea in gynecologic laparoscope a randomized trial. J Minim Invasive Gynecol. 2008; 15:26-31.
24. Leslie JB, Gan TJ. Meta-analysis of the safety of 5-HT3 antagonists with dexamethasone or droperidol for prevention of PONV. Ann Pharmacother. 2006; 40:856-872
25. Diemunsch P, Apfel C, Gan TJ et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin. 2007; 23:2559-2565 (Pubitemid 350033458)
26. Lewis IH, Campbell DN, Barrowcliffe MP. Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. Br J Anaesth. 1994; 73:244-246
27. Aapro MS. Palonosetron as an antiemetic and anti-nausea agent in oncology. Ther Clin Risk Manag. 2007; 3:1009-20.
28. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006; 17:1441-1449
29. Gaster LM, King FD. Serotonin 5-HT3 and 5-HT4 receptor antagonists. Med Res Rev. 1997; 17:163-214.
30. Rojas C, Stathis M, Thomas AG et al. Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor. Anesth Analg. 2008; 107(2):469-478
31. Wong EH, Clark R, Leung E et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995; 114:851-859
32. Clark RD, Miller AB, Berger J et al. 2-(Quinuclidin-3-yl)pyrido[4,3-b] indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists. J Med Chem. 1993; 36:2645-2657
33. Edsall JT. Hemoglobin and the origins of the concept of allosterism. Fed Proc. 1980; 39:226-235
34. Stoltz R, Cyong JC, Shah A et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004; 44:520-531 (Pubitemid 38509721)
35. Miller RC, Galvan M, Gittos MW et al. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-H3 receptors. Drug Development Research. 1993; 28:87-93. (Pubitemid 23041487)
36. Constenla M. 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Ann Pharmacother. 2004; 38:1683-1691 (Pubitemid 39297769)